$-0.68
(Market cap
$2,262 Mln
Revenue (TTM)
$65 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.5
-
Debt to Equity
--
-
Book Value
$4.4
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
129,696,087
10 Years Aggregate
CFO
$-811.94 Mln
EBITDA
$-781.36 Mln
Net Profit
$-756.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| -7.1 | 15.2 | 8.8 | 21.2 | 80.3 | 2.7 | 5.0 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| -8.9 | 784.0 | -62.2 | -39.4 | -43.5 | 15.2 | 78.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
|
16.8 | 2,261.9 | 120.3 | -57.5 | -108.2 | -9.9 | -- | 4.1 |
| 3.4 | 342.4 | 56.6 | -65.4 | -131.8 | -111.7 | -- | 8.6 | |
| 13.8 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 12.1 | 2,151.8 | 549.1 | 17.9 | -6.3 | 1.4 | 123.8 | 1.7 | |
| 4.5 | 178.2 | 0.0 | -57.6 | -- | -83 | -- | 2.4 | |
| 11.5 | 828.1 | 366.5 | 9.3 | 8.3 | 3.4 | 83.6 | 3.1 | |
| 3.6 | 654.8 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 13.5 | 834.1 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.8 | |
| 6.3 | 609.7 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 | |
| 25.5 | 2,927.9 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 5.0 |
Shareholding Pattern
View DetailsAbout Mesoblast - ADR
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal... lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Read more
-
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
-
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
-
Headquarters
Melbourne, VIC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mesoblast - ADR
What is the current share price of Mesoblast Limited - ADR Today?
The share price of Mesoblast Limited - ADR is $16.76 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Mesoblast Limited - ADR has given a return of 80.29% in the last 3 years.
What is the current PB & PE ratio of Mesoblast Limited - ADR?
Since, TTM earnings of Mesoblast Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-30.40 |
3.08 |
2025 |
-13.58 |
2.32 |
2024 |
-8.69 |
1.59 |
2023 |
-4.50 |
0.73 |
2022 |
-1.58 |
0.29 |
What is the 52 Week High and Low of Mesoblast Limited - ADR?
The 52-week high and low of Mesoblast Limited - ADR are Rs 21.50 and Rs 12.66 as of 01-Sep-2026.
What is the market cap of Mesoblast Limited - ADR?
Mesoblast Limited - ADR has a market capitalisation of $ 2,262 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mesoblast Limited - ADR?
Before investing in Mesoblast Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.